Workup of Painless Hematuria
All patients with painless hematuria require risk stratification followed by cystoscopy and upper tract imaging, with the intensity of evaluation determined by malignancy risk factors. 1, 2
Initial Assessment
Before any imaging, obtain:
- Properly collected urinalysis (microscopic evaluation showing ≥3 RBCs/HPF on one specimen, excluding infection, pyuria, bacteriuria, and contaminants) 2
- History and physical examination focusing on:
- Age, gender, smoking history
- Occupational chemical exposures
- Prior pelvic irradiation or chemotherapy
- Irritative voiding symptoms
- History of urologic disease or chronic UTI 2
- Serologic testing to evaluate for renal parenchymal disease
Risk Stratification
Gross (visible) hematuria carries 30-40% malignancy risk and mandates full urologic workup regardless of other factors 2
Microhematuria risk factors (2.6-4% malignancy risk):
- Male gender
- Age >35 years
- Smoking history
- Occupational chemical exposure
- Analgesic abuse
- History of urologic disease
- Irritative voiding symptoms
- Pelvic irradiation
- Chronic UTI or indwelling catheter
- Carcinogenic agent/chemotherapy exposure 2
Imaging Protocol
High-Risk Patients (Gross Hematuria or Multiple Risk Factors)
CT urography (CTU) is the imaging modality of choice 2, 3
CTU protocol includes:
- Unenhanced phase (stone detection)
- Nephrographic phase (renal parenchyma evaluation)
- Excretory phase (≥5 minutes post-contrast for urothelial visualization)
- Thin-slice acquisition with multiplanar reconstruction 2
Low-Risk Patients (Microhematuria, Age <40, Minimal Risk Factors)
Renal ultrasound is appropriate initial imaging to minimize radiation exposure 2, 3
Special Populations
- Pregnant patients: MR urography (heavily T2-weighted sequences without contrast) 2
- Renal insufficiency: MR urography or ultrasound 3
- Young patients <30 years: Consider ultrasound first 4
Cystoscopy
Cystoscopy must be performed in addition to imaging for complete evaluation, as it remains the gold standard for detecting bladder urothelial tumors 2, 3, 5
Exclude Before Full Workup
Do not proceed with complete imaging evaluation if benign cause identified:
- Active urinary tract infection (confirm with culture before antibiotics) 2
- Vigorous exercise within 48-72 hours
- Recent urologic procedure
- Active menstruation
- Recent trauma 2
Important caveat: If UTI suspected, treat and repeat urinalysis. Persistent hematuria after treatment requires full evaluation 2
Renal Parenchymal Disease
If proteinuria, dysmorphic RBCs, or RBC casts present suggesting glomerular disease:
- Concurrent nephrology evaluation is appropriate
- However, this does not preclude urologic evaluation as both processes can coexist 2
Anticoagulation
Anticoagulant therapy does not alter the evaluation approach—these patients require the same workup as non-anticoagulated patients 2
Follow-Up After Negative Evaluation
According to the most recent 2025 AUA/SUFU guidelines, most patients with negative risk-stratified hematuria evaluation do not require ongoing urologic monitoring and may be discharged after shared decision-making 1
Consider repeat urinalysis only in:
- Patients with multiple risk factors or heavy smoking history
- Development of gross hematuria
- New urologic symptoms
- Changes in clinical status 1
Critical pitfall: The malignancy detection rate after negative initial evaluation is very low (1.2-1.3%), and cancers typically appear >36 months later, making routine surveillance of limited yield 1